Castle Biosciences signals $385M-$395M 2026 revenue outlook as TissueCypher targets 50%-52% volume growth

GEO forecasts Q4 2026 revenue $777M-$827M with adjusted EBITDA $149M-$154M as ICE activations expand

Northwest Natural raises 2026 EPS guidance to $3.10-$3.20 as SiEnergy rate settlement and cost controls support outlook

Axon forecasts Q4 revenue of $990M-$1.01B while investing $1.2B in Skydio amid federal Dedrone timing uncertainty

BKV targets 400 MW Temple phase 1 as it continues to aim for a PPA in 2026 to early 2027